Literature DB >> 20336629

Modulation of basal and morphine-induced neuronal activity by a NPFF(2) selective agonist measured by c-Fos mapping of the mouse brain.

Lionel Moulédous1, Bernard Frances, Jean-Marie Zajac.   

Abstract

Neuropeptide FF (NPFF) is a neurotransmitter known to modulate opioid-induced analgesia, sensitization, and reward. The expression of the immediate early gene c-Fos was analyzed to map the distribution of neurons whose activity is regulated by central administration of the NPFF(2)-selective agonist dNPA in naive mice and in animals who had received a systemic injection of morphine. The number of c-Fos positive nuclei was quantified in 28 brain regions. Intracerebro-ventricular injection of 1 nmol dNPA alone produced an overall inhibition of basal c-Fos expression in the brain with a statistically significant decrease in the lateral ventral part of the bed nucleus of the stria terminalis, the medial preoptic area, and the medial parvicellular part of the paraventricular nucleus of the hypothalamus. In contrast, intraperitoneal injection of morphine 5 mg.kg(-1) induced a statistically significant increase in c-Fos expression in the prelimbic cortex, the nucleus accumbens core and shell, the ventral pallidum, the lateral hypothalamus, and the nucleus of the tractus solitarius. dNPA counteracted morphine effect only in the nucleus accumbens shell and the ventral pallidum. The inhibitory effects of a low dose of dNPA in the hypothalamus and its afferents suggest that NPFF(2) receptors negatively regulate the hypothalamic-pituitary-adrenal axis in mouse. Moreover, our study identified the nucleus accumbens shell and ventral pallidum as putative sites of interaction between NPFF and opioid systems in relation with the modulation of acute morphine rewarding and locomotor effects.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20336629     DOI: 10.1002/syn.20774

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  7 in total

1.  GRK2 protein-mediated transphosphorylation contributes to loss of function of μ-opioid receptors induced by neuropeptide FF (NPFF2) receptors.

Authors:  Lionel Moulédous; Carine Froment; Stéphanie Dauvillier; Odile Burlet-Schiltz; Jean-Marie Zajac; Catherine Mollereau
Journal:  J Biol Chem       Date:  2012-02-28       Impact factor: 5.157

2.  Heterologous regulation of Mu-opioid (MOP) receptor mobility in the membrane of SH-SY5Y cells.

Authors:  Kévin Carayon; Lionel Moulédous; Anne Combedazou; Serge Mazères; Evert Haanappel; Laurence Salomé; Catherine Mollereau
Journal:  J Biol Chem       Date:  2014-09-02       Impact factor: 5.157

Review 3.  Nonpeptide ligands of neuropeptide FF: current status and structural insights.

Authors:  Jessica V Mankus; Christopher R McCurdy
Journal:  Future Med Chem       Date:  2012-06       Impact factor: 3.808

4.  Involvement of protein degradation by the ubiquitin proteasome system in opiate addictive behaviors.

Authors:  Nicolas Massaly; Lionel Dahan; Mathieu Baudonnat; Caroline Hovnanian; Khaoula Rekik; Marcello Solinas; Vincent David; Stéphane Pech; Jean-Marie Zajac; Pascal Roullet; Lionel Mouledous; Bernard Frances
Journal:  Neuropsychopharmacology       Date:  2012-11-21       Impact factor: 7.853

Review 5.  Involvement of Mammalian RF-Amide Peptides and Their Receptors in the Modulation of Nociception in Rodents.

Authors:  Safia Ayachi; Frédéric Simonin
Journal:  Front Endocrinol (Lausanne)       Date:  2014-10-02       Impact factor: 5.555

6.  Tibial post fracture pain is reduced in kinin receptors deficient mice and blunted by kinin receptor antagonists.

Authors:  Vincent Minville; Lionel Mouledous; Acil Jaafar; Réjean Couture; Anne Brouchet; Bernard Frances; Ivan Tack; Jean-Pierre Girolami
Journal:  J Transl Med       Date:  2019-10-22       Impact factor: 5.531

Review 7.  Does Kisspeptin Belong to the Proposed RF-Amide Peptide Family?

Authors:  Seongsik Yun; Dong-Kyu Kim; Michael Furlong; Jong-Ik Hwang; Hubert Vaudry; Jae Young Seong
Journal:  Front Endocrinol (Lausanne)       Date:  2014-08-13       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.